Claim Check
From the latest edition of each brief.
Biotech & Pharma Intelligence
Five readouts checked against their registry records today. Two report their registered primaries; both RAS readouts lead with secondary endpoints; one TB trial gives no numbers for its primary.
| Readout | What the registry or primary source says | What the headline says | Verdict |
|---|---|---|---|
| ERAS-0015 · Erasca AURORAS-1 · NCT06983743 (opens another website in a new tab) | Registered as Phase 1. Primaries: dose-limiting toxicities, maximum tolerated dose, recommended dose, adverse events, pharmacokinetics; response rate secondary. N=600 (planned); recruiting; primary completion 05.2028. | Confirmed response rate 44% (n=25) in pancreatic cancer at 32 mg; no dose-limiting toxicities | Partial |
| Daraxonrasib + chemotherapy · Revolution Medicines RMC-GI-102 · NCT06445062 (opens another website in a new tab) (our match) | Phase 1/2 platform. Primaries for Subprotocols A to F, including the chemotherapy combination: adverse events and dose-limiting toxicities; response, progression-free and overall survival secondary. N=1,130 (planned); recruiting; primary completion 09.30.2028. | Response rate 60.7%, median progression-free survival 12.8 months (n=61) | Partial |
| Xanamem · Actinogen XanaMIA · NCT06125951 (opens another website in a new tab) | Phase 2/3. Primaries: CDR-SB change at 36 weeks; adverse events. N=247; active, not recruiting; primary completion 09.22.2026. | Primary missed: 0.10 points vs placebo, p = 0.65 | Match |
| Barzolvolimab · Celldex Atopic dermatitis · NCT06727552 (opens another website in a new tab) | Phase 2. Primary: percent change in itch score (PP-NRS) at week 16. N=131; active, not recruiting; primary completion 05.06.2026. | Primary missed at both doses; program stopped | Match |
| AlpE · BioVersys ENABLE · NCT06748937 (opens another website in a new tab) | Phase 2. Primary: early bactericidal activity over 14 days. N=60 (planned). Still reads recruiting past its 03.2026 primary completion date. | All regimens bactericidal; no values given | Open |
ClinicalTrials.gov records pulled 11.20.2026 Reg; company releases (11.19 and 11.20) Co. Revolution’s release names the study, RMC-GI-102, but gives no registry number, so its record is our match by drug and design. A verdict compares what was announced with what was registered; it says nothing about whether the drug works.
AI & Technology Intelligence
For each headline we opened the primary document where we could. Two match, one is partial and three are open.
| Claim | What the primary document says | What the headline says | Verdict |
|---|---|---|---|
| Anthropic’s raise Closing release | Gross IPO proceeds about $93.5B; placement about $26.0B Co | Anthropic raises almost $120 billion | Match |
| Chip licenses Committee release | 3.4 million chips requested; more than 879,000 approved Gov | Nearly 880,000 AI chips approved for China | Match |
| Commerce rule in force Federal Register | Effective on publication, 11.19, per a law firm summary; Federal Register page not opened Press | Remote-access chip rule takes effect | Open |
| Correction Index data | S&P 500 11.62% below its 10.06 record close; Dow close not confirmed by us Data | S&P 500 and Dow close in correction | Partial |
| AMD firmware No primary | No agency document; Hunterbrook says it cannot show a violation | Short seller ties AMD firmware to blacklisted firm | Open |
| Nvidia and Inception No filing | No announcement by either company | Nvidia nears deal for Inception | Open |

